Last reviewed · How we verify

Lignocaine

University of Malaya · FDA-approved active Small molecule ✓ Verified May 2026 Quality 19/100

Lignocaine is a Small molecule drug developed by University of Malaya. It is currently FDA-approved for Hemorrhoids, Infestation by Phthirus pubis, Infestation by Sarcoptes scabiei var hominis. Also known as: Intravenous lignocaine, xylocaine, 2% lignocaine 1 ml, Lidocaine.

Lignocaine, also known as lidocaine, is a small molecule local anesthetic of the amino amide type. It is used to treat pain, including postoperative pain and shoulder pain, and is typically effective for half an hour to three hours when used for local anesthesia or in nerve blocks.

At a glance

Generic nameLignocaine
Also known asIntravenous lignocaine, xylocaine, 2% lignocaine 1 ml, Lidocaine, Lignocaine infusion
SponsorUniversity of Malaya
Target5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Lignocaine

What is Lignocaine?

Lignocaine is a Small molecule drug developed by University of Malaya, indicated for Hemorrhoids, Infestation by Phthirus pubis, Infestation by Sarcoptes scabiei var hominis.

What is Lignocaine used for?

Lignocaine is indicated for Hemorrhoids, Infestation by Phthirus pubis, Infestation by Sarcoptes scabiei var hominis, Itching of skin, Local Anesthesia for Endotracheal Intubation.

Who makes Lignocaine?

Lignocaine is developed and marketed by University of Malaya (see full University of Malaya pipeline at /company/university-of-malaya).

Is Lignocaine also known as anything else?

Lignocaine is also known as Intravenous lignocaine, xylocaine, 2% lignocaine 1 ml, Lidocaine, Lignocaine infusion.

What development phase is Lignocaine in?

Lignocaine is FDA-approved (marketed).

What does Lignocaine target?

Lignocaine targets 5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing